We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.06%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$225M
AUM Growth
+$33.3M
Cap. Flow
+$42.3M
Cap. Flow %
18.83%
Top 10 Hldgs %
56.68%
Holding
48
New
12
Increased
15
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.6M
2
THOR
THORATEC CORPORATION
THOR
+$12M
3
ACHV icon
Achieve Life Sciences
ACHV
+$11.8M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$9.18M
5
ARDM
Aradigm Corp Common Stock
ARDM
+$9.11M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$17.9M
2
FLNA
Filana Therapeutics
FLNA
+$3.13M
3
PLX icon
Protalix BioTherapeutics
PLX
+$3M
4
CYTK icon
Cytokinetics
CYTK
+$2.99M
5
NSPH
NANOSPHERE INC. COM NEW
NSPH
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 74.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
26
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.56M 1.14%
131,967
-33,333
-20% -$588K
FRTX
27
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.55M 1.13%
+664
New +$2.5M
AVNR
28
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$2.54M 1.13%
+450,000
New +$2.07M
NUWE icon
29
Nuwellis
NUWE
$160K
– –
0
– –
OCRX
30
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.27M 1.01%
296,944
-14,877
-5% -$119K
KBIO
31
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$2.08M 0.92%
113,837
+46,725
+70% +$800K
EYPT icon
32
EyePoint Inc
EYPT
$1.03B
$1.65M 0.73%
37,906
+9,575
+34% +$361K
INO icon
33
PUT
Inovio Pharmaceuticals
INO
$55.7M
$1.36M 0.61%
+10,500
New +$1.24M
PLXP
34
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$1.2M 0.54%
15,516
-15,734
-50% -$1.22M
LITS
35
Lite Strategy Inc
LITS
$32.8M
$1M 0.44%
7,883
– –
STRM
36
DELISTED
Streamline Health Solutions
STRM
$728K 0.32%
10,107
– –
PLX icon
37
Protalix BioTherapeutics
PLX
$191M
$612K 0.27%
16,779
-74,437
-82% -$3M
TRAW icon
38
Traws Pharma
TRAW
$6.85M
$594K 0.26%
+2
New +$590K
ACHV icon
39
CALL
Achieve Life Sciences
ACHV
$659M
– –
-59
Closed -$1.53M
CYTK icon
40
Cytokinetics
CYTK
$10.5B
– –
-315,000
Closed -$2.99M
MNKD icon
41
CALL
MannKind Corp
MNKD
$1.21B
– –
-105,400
Closed -$2.12M
MNKD icon
42
MannKind Corp
MNKD
$1.21B
– –
-109,380
Closed -$2.2M
OFIX icon
43
PUT
Orthofix Medical
OFIX
$477M
– –
-265,000
Closed -$7.99M
VIRX
44
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-922
Closed -$1.28M
CCXI
45
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-249,700
Closed -$1.66M
MNTA
46
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-62,000
Closed -$722K
NSPH
47
DELISTED
NANOSPHERE INC. COM NEW
NSPH
– –
-64,015
Closed -$2.75M
FURX
48
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-205,858
Closed -$17.9M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2014 Portfolio in Review

As of Q2 2014, Great Point Partners held 48 positions worth $225M, up 17% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners deployed $42.3M of net new capital in Q2 2014, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was THORATEC CORPORATION: 360,000 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 67% a quarter earlier.

On the sell side, the largest reduction was Filana Therapeutics, an estimated $3.13M trimmed.

  • Great Point Partners's largest Q2 2014 buy was THORATEC CORPORATION: 360,000 shares worth $12.6M.
  • Great Point Partners added most to Neurocrine Biosciences in Q2 2014, an estimated $12.6M increase.
  • Great Point Partners's biggest Q2 2014 reduction was Filana Therapeutics, cutting an estimated $3.13M.
  • Great Point Partners fully exited FURIEX PHARMACEUTICALS INC COM STK (DE) in Q2 2014, selling an estimated $17.9M.
  • Great Point Partners's ten largest holdings make up 57% of its $225M portfolio in Q2 2014.
  • Great Point Partners opened 12 new positions and closed 10 in Q2 2014.
  • Great Point Partners's portfolio value rose 17% quarter-over-quarter to $225M.

Based on Great Point Partners's 13F filing for Q2 2014, filed 14 Aug 2014.